PRX-07034

From Self-sufficiency
Jump to: navigation, search
PRX-07034
File:PRX-07034 structure.png
Systematic (IUPAC) name
N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number ?
ATC code none
PubChem CID 11532574
Chemical data
Formula C21H29Cl2N3O4S
Molar mass 490.44 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

PRX-07034 is a selective 5-HT6 receptor antagonist.[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.[1][2][3][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][6][7]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity". Drugs. 67 (1): 27–55. PMID 17209663. 
  3. "PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials". 
  4. 6.0 6.1 "Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009". 
  5. "Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction".